Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - sodium chloride 9 g/l;  ;  ;  ;  ;   - solution for infusion - 0.9 % - active: sodium chloride 9 g/l           excipient: hydrochloric acid sodium hydroxide water for injection - for the restoration and maintenance of salt and extracellular fluid levels or as a vehicle for the administration of parenteral drugs.

Airija - anglų - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals (ireland) ltd - sodium chloride - solution for injection - 0.9 %w/v - electrolyte solutions

Malta - anglų - Medicines Authority

demo s.a. pharmaceutical industry 21st km national road athens - lamia 14568 krioneri, greece - sodium chloride - solution for injection - sodium chloride 9 mg/ml - blood substitutes and perfusion solutions

Australija - anglų - APVMA (Australian Pesticides and Veterinary Medicines Authority)

conquest crop protection pty ltd - dicamba as the sodium salt - water soluble granules - dicamba as the sodium salt benzoic acid-arylaliphatic active 700.0 g/kg - herbicide

Australija - anglų - APVMA (Australian Pesticides and Veterinary Medicines Authority)

adama australia pty limited - acifluorfen as the sodium salt - aqueous concentrate - acifluorfen as the sodium salt diphenyl ether active 224.0 g/l - herbicide

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

jubilant draximage inc., dba jubilant radiopharma - sodium iodide i-131 (unii: 29vco8achh) (iodide ion i-131 - unii:4gc1foq22u) - iodide ion i-131 100 mci - sodium iodide i 131 capsules diagnostic is indicated for use in adults for: - assessment of thyroid function using radioactive iodine (rai) uptake test - imaging the thyroid (scintigraphy) sodium iodide i 131 capsules diagnostic is contraindicated in pregnancy [see warnings and precautions (5.1) , use in specific populations (8.1) ]. risk summary sodium iodide i 131 capsules diagnostic is contraindicated in pregnancy because fetal exposure can lead to neonatal hypothyroidism, which in some cases is severe and irreversible. data from the published literature describe reports of neonatal thyroid abnormalities after fetal exposure, including agenesis of the thyroid and hypothyroidism (see clinical considerations, data ). no animal reproductive studies have been conducted. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnanc

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

bi-coastal pharma international llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 98 mg in 1 g - indications: sodium sulfacetamide 9.8% and sulfur 4.8% cleanser is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. contraindications: sodium sulfacetamide 9.8% and sulfur 4.8% cleanser is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. sodium sulfacetamide 9.8% and sulfur 4.8% cleanser is not to be used by patients with kidney disease.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - sodium ferric gluconate complex (unii: cc9149u2qx) (ferric cation - unii:91o4lml611) - ferric cation 12.5 mg in 1 ml - sodium ferric gluconate complex in sucrose injection is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. sodium ferric gluconate complex in sucrose injection is contraindicated in patients with known hypersensitivity to sodium ferric gluconate or any of its components. reactions have included anaphylaxis [see warnings and precautions (5.1) ]. risk summary parenteral iron administration may be associated with hypersensitivity reactions [see warnings and precautions (5.1) ], which may have serious consequences, such as fetal bradycardia (see clinical considerations ). advise pregnant women of the potential risk to the fetus. available data from postmarketing reports with sodium ferric gluconate complex in sucrose injection use in pregnancy are insufficient to assess the risk of major birth defects and miscarriage. sodium ferric gluconate comple

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - sodium ferric gluconate complex (unii: cc9149u2qx) (ferric cation - unii:91o4lml611) - ferric cation 12.5 mg in 1 ml - sodium ferric gluconate complex in sucrose injection is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. sodium ferric gluconate complex in sucrose injection is contraindicated in patients with known hypersensitivity to sodium ferric gluconate or any of its components. reactions have included anaphylaxis [see warnings and precautions (5.1) ]. risk summary parenteral iron administration may be associated with hypersensitivity reactions [see warnings and precautions (5.1) ], which may have serious consequences, such as fetal bradycardia (see clinical considerations ). advise pregnant women of the potential risk to the fetus. available data from postmarketing reports with sodium ferric gluconate complex in sucrose injection use in pregnancy are insufficient to assess the risk of major birth defects and miscarriage. sodium ferric gluconate comple

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

acella pharmaceuticals, llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 9 mg in 1 g - indications: sodium sulfacetamide 9% - sulfur 4.5% wash is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. contraindications: sodium sulfacetamide 9% - sulfur 4.5% wash is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or ony other component of this preparation. sodium sulfacetamide 9% - sulfur 4.5% wash is not to be used by patients with kidney disease.